UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.35), versus the analyst estimate of ($1.23).

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery